Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01465802 · ClinicalTrials.gov registry record · Phase 2
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 236
- Enrollment target
NCT01465802 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 236 participants.
The verdict
NCT01465802, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 236 participants
- Enrollment target
Study Summary
To assess the impact of prophylactic treatment on the incidence of adverse events in advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent. To assess the impact of an interrupted dacomitinib dosing schedule in Cycle 1 on the incidence of adverse events in first-line advanced NSCLC patients with an EGFR mutation (HER-1 mutation, HER-2 mutation or HER-2 amplification).
Interventions
- DRUG Doxycycline
- DRUG Dacomitinib
- DRUG Probiotic
- DRUG Alclometasone cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2011-12-26 |
| Est. Completion | 2015-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01465802
The ClinicalTrials.gov registry entry for NCT01465802 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 236 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Doxycycline is the first listed.
NCT01465802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01465802 about?
NCT01465802 is a clinical study titled "Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO". To assess the impact of prophylactic treatment on the incidence of adverse events in advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent. To assess the impact of an interrupted dacomitinib dosing schedule in Cycle 1 on the incidence of adverse events in first...
What is the current status of trial NCT01465802?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 236 participants. The study started on 2011-12-26. Estimated completion is 2015-05-18.
What interventions are being tested in trial NCT01465802?
The interventions under investigation include: Doxycycline (DRUG), Dacomitinib (DRUG), Probiotic (DRUG), Alclometasone cream (DRUG).
Who is sponsoring clinical trial NCT01465802?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.